

031504

Express Mail Label No. EV386751515US

04/22 U.S. PTO

**UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)***(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.
5047 CONTotal Pages in this Submission
67**TO THE COMMISSIONER FOR PATENTS**Mail Stop Patent Application
P.O. Box 1450
Alexandria, VA 22313-1450

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

EXPRESSION SYSTEM FOR RECOMBINANT PROTEINS

and invented by:

Nick Wan et al.

If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☒ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: 10/045,507

Which is a:

☒ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: 60/248,806

Which is a:

☐ **Continuation** ☐ **Divisional** ☐ **Continuation-in-part (CIP)** of prior application No.: _____

Enclosed are:

Application Elements

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 29 pages and including the following:
 - a. ☒ Descriptive Title of the Invention
 - b. ☐ Cross References to Related Applications *(if applicable)*
 - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
 - d. ☐ Reference to Sequence Listing, a Table, or a Computer Program Listing Appendix
 - e. ☒ Background of the Invention
 - f. ☒ Brief Summary of the Invention
 - g. ☒ Brief Description of the Drawings *(if filed)*
 - h. ☒ Detailed Description
 - i. ☒ Claim(s) as Classified Below
 - j. ☒ Abstract of the Disclosure

22857 U.S. PTO
10/800602

031504

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
5047 CON

Total Pages in this Submission
67

Application Elements (Continued)

3. ☒ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
- a. ☐ Formal Number of Sheets _____
- b. ☒ Informal Number of Sheets 11
4. ☒ Oath or Declaration
- a. ☐ Newly executed *(original or copy)* ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) *(for continuation/divisional application only)*
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
- d. ☐ DELETION OF INVENTOR(S)
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).
5. ☐ Incorporation By Reference *(usable if Box 4b is checked)*
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ CD ROM or CD-R in duplicate, large table or Computer Program (Appendix)
7. ☒ Application Data Sheet (See 37 CFR 1.76)
8. ☐ Nucleotide and/or Amino Acid Sequence Submission *(if applicable, all must be included)*
- a. ☐ Computer Readable Form (CRF)
- b. ☐ Specification Sequence Listing on:
- i. ☐ CD-ROM or CD-R (2 copies); or
- ii. ☐ Paper
- c. ☐ Statement(s) Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

9. ☒ Assignment Papers *(cover sheet & document(s))*
10. ☒ 37 CFR 3.73(B) Statement *(when there is an assignee)*
11. ☐ English Translation Document *(if applicable)*
12. ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations
13. ☐ Preliminary Amendment
14. ☒ Return Receipt Postcard (MPEP 503) *(Should be specifically itemized)*
15. ☐ Certified Copy of Priority Document(s) *(if foreign priority is claimed)*
16. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail *(Specify Label No.):* EV386751515US

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Total Pages in this Submission
67

17. ☐ Additional Enclosures (please identify below):

| |
|--|
| |
|--|

18. ☐ Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
5047 CON


Total Pages in this Submission
67

Fee Calculation and Transmittal

CLAIMS AS FILED

| For | #Filed | #Allowed | #Extra | Rate | Fee |
|--|--------|----------|--------|-----------|----------|
| Total Claims | 17 | - 20 = | 0 | x \$18.00 | \$0.00 |
| Indep. Claims | 5 | - 3 = | 2 | x \$84.00 | \$168.00 |
| Multiple Dependent Claims (check if applicable) <input type="checkbox"/> | | | | | \$0.00 |
| BASIC FEE | | | | | \$750.00 |
| OTHER FEE (specify purpose) _____ | | | | | |
| TOTAL FILING FEE | | | | | \$918.00 |

- ☐ A check in the amount of _____ to cover the filing fee is enclosed.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 07-1074 as described below.
- ☒ Charge the amount of \$918.00 as filing fee.
 - ☒ Credit any overpayment.
 - ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
 - ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).


Signature

Jennifer L. Dupre
Reg. No. 41, 722
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
Tel. (617) 768-6523
Fax (617) 252-7553

Dated: March 15, 2004

cc:

Express Mail Label No. EV386751515US

Docket Number 5047 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|---------------|---|---|
| Applicants | : | Nick Wan et al. |
| Serial Number | : | Not Yet Assigned |
| Examiner | : | Not Yet Assigned |
| Art Unit | : | Not Yet Assigned |
| Filed | : | Filed Herewith |
| For | : | EXPRESSION SYSTEM FOR RECOMBINANT PROTEINS |

Commissioner for Patents
United States Patent and Trademark Office
Alexandria, VA 22313-1450

STATEMENT UNDER 37 C.F.R. § 3.73(b)

Sir:

This Statement Under 37 C.F.R. § 3.73(b) accompanies a POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST, filed in the above-identified application concurrently herewith.

Evidence establishing that Genzyme Corporation is the assignee of the entire right, title and interest in the above-identified application, may be found in the Assignment recorded on November 7, 2001 at Reel 014098 and Frames 0761 and 0729.

Evidence that the undersigned is authorized to act on behalf of Genzyme may be found in the attached SIGNATURE AUTHORITY.

Respectfully submitted,



Madge R. Kanter (Reg. No. 35,211)
Attorney for Applicant
Genzyme Corporation
500 Kendall Street
Cambridge, Massachusetts 02142
Tel. (617) 768-6485

Dated: March 15, 2004